Siddharth Mittal Succeeds Peter Bains As CEO & MD Of Syngene

Syngene International Limited appointed Siddharth Mittal as Chief Executive Officer and Managing Director (CEO & MD), effective July 1, 2026. The company said this follows the completion of the tenure of Peter Bains on June 30, 2026.

Siddharth Mittal worked at Biocon Ltd. earlier, where he served as CEO & MD after his role as Chief Financial Officer (CFO). His experience spans about 30 years across business roles. Earlier, he was President and CFO at Biocon from July 2014 to November 2019. He also held roles including Vice President (VP) of Finance, Symphony Teleca Corporate Controller, and CFO at Cambridge Solutions. He began his career as a Chartered Accountant at S R Batliboi & Co LLP. He believes healthcare enables a better quality of life and emphasises integrity, collaboration, execution excellence, and leading by example, with continuous learning and adaptability as key principles for leadership.

Peter Bains has over three decades of experience in pharmaceuticals and biotechnology. At Syngene, he leads strategy and execution, oversees investments, heads the executive team, and manages business operations. He was CEO of Sosei Group (now Nxera Pharma) and spent 23 years at GlaxoSmithKline, holding senior roles including Head of Global Marketing and SVP Commercial Development for international regions. He also served as CEO and Board member of Syngene for nearly six years from 2010, leading its successful listing in 2015. He served as CEO of Syngene from 2010 to 2015, leading its listing. Bains has global leadership experience across Board, CEO, and senior roles, with a track record of building companies, teams, brands, and businesses. His expertise spans biopharmaceuticals, including biotechnology, vaccines, branded generics, life sciences, and CRO across advanced and emerging markets.

a

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: